Published in Circulation on July 19, 2004
Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J (2014) 1.12
A more aggressive approach to emergency embolectomy for acute pulmonary embolism. Mayo Clin Proc (2010) 0.98
Aggressive approach to pulmonary embolectomy for massive acute pulmonary embolism: a historical and contemporary perspective. Mayo Clin Proc (2010) 0.97
Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer (2010) 0.88
tPA regulates pulmonary vascular activity through NMDA receptors. Am J Physiol Lung Cell Mol Physiol (2011) 0.84
Management of massive and nonmassive pulmonary embolism. Arch Med Sci (2012) 0.84
Thrombolytic treatment (alteplase; rt-Pa) in acute massive pulmonary embolism and cardiopulmonary arrest. Drug Des Devel Ther (2014) 0.83
Fatal pulmonary embolism update: 10 years of autopsy experience at an academic medical center. JRSM Short Rep (2013) 0.82
Acute lung failure. Semin Respir Crit Care Med (2011) 0.81
Recent advances in the management of pulmonary embolism: focus on the critically ill patients. Ann Intensive Care (2016) 0.81
Acute pulmonary embolism after pneumonectomy. J Thorac Dis (2012) 0.81
Surgical embolectomy for acute massive pulmonary embolism. Int J Clin Exp Med (2014) 0.80
Pulmonary embolism, part II: Management. Exp Clin Cardiol (2013) 0.80
Review of acute pulmonary embolism in a general hospital. Surg Today (2007) 0.80
Thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism. Exp Ther Med (2013) 0.79
Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Initial thrombolysis treatment compared with anticoagulation for acute intermediate-risk pulmonary embolism: a meta-analysis. J Thorac Dis (2015) 0.77
Aggressive management of pulmonary embolism. Semin Intervent Radiol (2012) 0.77
Management of pulmonary embolism with rheolytic thrombectomy. Can Respir J (2011) 0.75
Systemic thrombolysis increases hemorrhagic stroke risk without survival benefit compared with catheter-directed intervention for the treatment of acute pulmonary embolism. J Vasc Surg Venous Lymphat Disord (2017) 0.75
Inertial Cavitation Ultrasound with Microbubbles Improves Reperfusion Efficacy When Combined with Tissue Plasminogen Activator in an In Vitro Model of Microvascular Obstruction. Ultrasound Med Biol (2017) 0.75
Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report. Int J Emerg Med (2010) 0.75
New anticoagulants emerge, how can we use them for acute pulmonary embolism? J Thorac Dis (2012) 0.75
Thrombolysis in submassive pulmonary embolism, prudent or puerile? BMJ Case Rep (2013) 0.75
Emergent surgical pulmonary embolectomy in a pregnant woman: case report and literature review. Tex Heart Inst J (2014) 0.75
Surgical embolectomy in the management of massive and sub-massive pulmonary embolism: The results of 30 consecutive ill patients. ARYA Atheroscler (2015) 0.75
Outcome of thrombolysis for massive pulmonary embolism. Ghana Med J (2009) 0.75
Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient. Hippokratia (2015) 0.75
Comparing different thrombolytic dosing regimens for treatment of acute pulmonary embolism. Crit Care (2010) 0.75
Transcatheter Therapy for a Large Mobile Right Atrial Thrombus and Massive Pulmonary Embolism. J Invasive Cardiol (2016) 0.75
Systemic Thrombolysis for Pulmonary Embolism: A Review. P T (2016) 0.75
Recombinant tissue plasminogen activator plus heparin compared with heparin alone for patients with acute submassive pulmonary embolism: one-year outcome. J Geriatr Cardiol (2013) 0.75
Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death. Evid Based Nurs (2005) 0.75
Unloading of right ventricle and clinical improvement after ultrasound-accelerated thrombolysis in patients with submassive pulmonary embolism. Case Rep Med (2014) 0.75
Pharmaco-mechanical management of acute massive pulmonary embolism in a postpartum female. Indian Heart J (2013) 0.75
Impact of catheter fragmentation followed by local intrapulmonary thrombolysis in acute high risk pulmonary embolism as primary therapy. Indian Heart J (2014) 0.75
Recombinant tissue plasminogen activator for massive pulmonary thromboembolism. BMJ Case Rep (2013) 0.75
Massive pulmonary embolus with hemodynamic compromise: therapeutic options. Emerg Radiol (2006) 0.75
Surgical Embolectomy for Acute Pulmonary Thromboembolism. Ann Vasc Dis (2017) 0.75
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med (2002) 3.91
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg (2014) 3.43
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust (2004) 3.34
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Medical treatment of peripheral arterial disease. JAMA (2006) 2.76
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med (2004) 2.65
Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol (2012) 2.63
Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke (2007) 2.60
Aspirin resistance. Lancet (2006) 2.54
Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation (2007) 2.54
Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet (2009) 2.53
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J (2010) 2.52
Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40
Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust (2005) 2.20
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol (2005) 2.14
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol (2003) 2.13
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest (2006) 1.85
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82
A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J (2004) 1.80
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75
Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res (2009) 1.72
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med (2012) 1.67
Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2008) 1.65
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation (2005) 1.63
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood (2012) 1.59
The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust (2008) 1.57
Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med (2006) 1.56
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med (2008) 1.54
Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52
Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49
Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke (2006) 1.46
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45
Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv (2011) 1.45
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J (2005) 1.39
Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med (2010) 1.39
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med (2006) 1.34
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med (2008) 1.33
Does this patient have pulmonary embolism? JAMA (2003) 1.30
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med (2011) 1.26
Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ) (2010) 1.25
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation (2010) 1.20
Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol (2012) 1.18
Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke (2003) 1.16
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol (2005) 1.14
Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation (2012) 1.14
Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis (2007) 1.12
Outcome in patients with stroke associated with internal carotid artery occlusion. Cerebrovasc Dis (2005) 1.12
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol (2010) 1.09
Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost (2002) 1.09
New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol (2013) 1.08
What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Thromb Res (2006) 1.08
Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol (2013) 1.05
The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol (2009) 1.05
Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med (2002) 1.04